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Introduction 
Colorectal cancer (CRC) is the second leading cause of cancer deaths in both men and 
women in the United States (U.S. Cancer Statistics Working Group, 2013).  In 2011, 51,783 
people died from CRC (Centers for Disease Control and Prevention [CDC], 2014a).  CRC can be 
prevented by utilizing routine screening recommended by U.S. Preventive Service Task Force 
(USPSTF, 2008).  USPSTF (2008) recommends people with average-risk be screened for CRC 
at age 50 years and older.  Current low CRC screening rate at 64.5% in 2010 (CDC, 2013a) 
indicates that many more Americans will be diagnosed with CRC in the future.  Researchers 
studying the causes of low participation in CRC screening have recognized that there are barriers 
related to use of invasive test methods (flexible sigmoidoscopy and colonoscopy) such as 
uninsured status, and lack of providers’ recommendation.  Fecal occult blood test (FOBT) such 
as high-sensitivity FOBT or fecal immunochemical test (FIT) is one of the recommended tests by 
USPSTF.  A low sensitivity of gFOBT for detecting polyps and CRC is considered to be a major 
barrier in its utilization which is low at 10.4% as a screening modality (CDC, 2013b).   
In an effort to increase CRC screening rates, to improve utilization of FOBT may be 
worth investigating.  The initial focus of this DNP practice inquiry project was to examine the 
efficacy of FOBT and if utilization of FOBT will be a reliable test methods in detecting polyps 
or CRC.  The first manuscript is a literature review of studies published between 2008 and 2015 
that focused on the efficacy of FOBTs in people aged 50 years and older.  During this review, 
FOBT was recognized as optimal alternative tests for those who are reluctant to undergo an 
invasive method for CRC screening although the efficacy of FIT is not as high as the efficacy of 
colonoscopy.   With the findings from the literature review, the next step of this project was to 
identify a strategy that can promote increasing the utilization of FOBT.  The second manuscript 
3 
 
evaluates an innovative program known as FluFOBT program to examine the potential impacts 
on improving CRC screening rates among low-income eligible adults.  Findings from conducting 
an evaluation of the program showed its effectiveness in increasing CRC screening rates and 
having significant cost benefits.  These findings led to curiosity about what advanced practice 
registered nurses (APRN) know of the current CRC screening recommendation guidelines and 
their attitude toward making a referral for CRC screening.  The final manuscript focuses on 
examining the relationship between the APRN knowledge level of the current CRC screening 
recommendation guidelines and their self-reported referral rates of CRC screening by conducting 
online survey via Kentucky Coalition of Nurse Practitioners and Nurse Midwives listserv.        
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Abstract 
Colorectal Cancer (CRC) is the second leading cause of cancer deaths in both men and 
women in the United States.  In 2011, 51,783 people including 26,804 men and 24,979 women 
died in 2011.  Evidence-based CRC screening guidelines by U.S. Preventive Service Task Force 
(USPSTF, 2008) recommend a high-sensitivity fecal occult blood test (guaiac FOBT) and fecal 
immunochemical test (FIT) annually, but the utilization of both tests is low at 10.4%.  Offering 
non-invasive methods to those who are reluctant to participate in CRC screening may be worth 
investigating.  The purpose of this review of literature is to describe the efficacy of FOBT 
(guaiac-based FOBT [gFOBT] & fecal immunochemical test [FIT]) in screening CRC.  Findings 
showed that FIT compared with gFOBT is superior in detecting CRC and advanced neoplasia 
and participating rates.   
Keywords: colorectal cancer screening, screening modalities, fecal occult blood test, 
fecal immunochemical test, efficacy, fecal occult blood test randomized controlled trial, and 
fecal occult blood test systemic review. 
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Efficacy Fecal Occult Blood Test: 
A Literature Review 
Introduction 
Colorectal cancer (CRC) is the second leading cause of cancer deaths in both men and 
women in the United States (U.S. Cancer Statistics Working Group, 2013).  Although CRC 
deaths have been declining over the past two decades, 51,783 people including 26,804 men and 
24,979 women died in 2011(Centers for Disease Control and Prevention [CDC], 2014) and 
nearly 50,310 were projected to die from it in 2014 (American Cancer Society [ACS], 2014a; 
Siegel, DeSantis, & Jemal, 2014).  The incidence rates of CRC also have been decreasing by an 
average of 3.4% yearly over the past 10 years (Siegel et al., 2014).  Regardless, 135,260 people 
were diagnosed with CRC in 2011 (CDC, 2014) and nearly136, 000 were expected to be 
diagnosed with CRC in 2014(Siegel et al., 2014).  Incidence and death of CRC can be 
substantially reduced when recommended screening tests by U.S. Preventative Service Task 
Force (USPSTF, 2008) are properly utilized for eligible adults.  Regrettably, the low CRC 
screening rate at 64.5% in 2010 (CDC, 2013a) indicates that many more American will be 
diagnosed with CRC in the future.   
Research suggests that one barrier for CRC screening may be use of invasive methods 
such as sigmoidoscopy and colonoscopy.  Offering non-invasive methods to those who are 
reluctant to participate in CRC screening may be worth investigating.  The purpose of this review 
of literature is to describe efficacy of FOBT in screening CRC. 
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Background 
Detecting polyps or CRC at an early stage can be challenging as, generally, there are no 
apparent signs and symptoms.  Even when CRC advances, the nonspecific nature of 
gastrointestinal symptoms makes it difficult to recognize CRC without appropriate tests.  These 
nonspecific gastrointestinal symptoms include abdominal pain, rectal bleeding, anemia, 
unintended weight loss, and alteration in bowel habits (Jednak & Nostrant, 1998; Tomlinson, 
Wong, Au, & Schiller, 2012).  CRC screening guidelines from USPSTF (2008) recommends 
people with average-risk (i.e. those who have no family history of colorectal neoplasia) be 
screened for CRC at age 50 years and older.  Currently, there are several tests detecting CRC 
including  sigmoidoscopy, standard colonoscopy, virtual (CT) colonoscopy, double contrast 
barium enema, fecal occult blood tests (FOBT) and stool DNA, (ACS, 2014b; National Cancer 
Institute[NCI], 2014a).  The USPSTF CRC screening guidelines recommend utilization of the 
following three tests; high-sensitivity fecal occult blood test (FOBT) including fecal 
immunochemical test (FIT), sigmoidoscopy with FOBT, and colonoscopy (USPSTF, 2008).  
According to USPSTF CRC screening recommendations guidelines, high sensitivity FOBT or 
FIT (annually), sigmoidoscopy with FOBT (every 5 years with every 3 years), and colonoscopy 
(every 10 years) are recommended for adults with average risk (USPSTF, 2008).  A colonoscopy 
is recommended as a follow-up test for people with abnormal findings as it is considered the gold 
standard procedure for making a diagnosis and preventing CRC by many expert medical groups. 
Although effectiveness of these modalities in detecting polyps or CRC has been 
demonstrated in numerous studies, current low CRC screening rates indicate an under-utilization 
of these tests.  Willingness to undergo a CRC screening test may be an important step for the 
eligible adults.  Researchers studying the causes of low participation in CRC screening have 
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recognized that there are barriers related to the tests that use invasive methods.  In an effort to 
increase CRC screening rates, offering non-invasive methods to those who are reluctant to 
participate in CRC screening may be worth investigating.  FOBT and FIT are both non-invasive 
methods recommended as screening tests by USPSTF, but the utilization of them are low at 10.4% 
(CDC, 2013b).  Both high- sensitivity FOBT and FIT examine feces to detect occult blood and 
can be done at a user’s convenience at his or her home.  This may be an applicable choice for 
those who are unwilling to undergo colonoscopy or sigmoidoscopy. 
FOBT was introduced around 1970 and has been evolving since then (Schapiro, 2007).  
FOBT detects hidden blood products in stool by using chemical guaiac.  The concept of 
detecting occult blood in stool by using guaiac gum was credited to Van Deen in 1864 (Simon, 
1985).  This principle is based on the idea that the fragile blood vessels at the surface of enlarged 
polyps and CRC are easily damaged by the passing feces (ACS, 2014b).  FOBT is divided into 
two groups; guaiac-based (gFOBT) and immunochemical (iFOBT or FIT).  The earlier method 
known as gFOBT relies on detecting heme, the pigment-producing component of hemoglobin 
(Young, St. John, Rose, & Blake, 1990; Young, 2004).  A reaction between heme and a 3-6% 
hydrogen peroxide developer in ethanol or methanol results in oxidation of guaiac causing the 
appearance of a blue color (Carroll, Seaman, & Halloran, 2014).  GFOBT requires moderate 
amount of heme in order to produce the appearance of blue color, (Young et al., 2014).  However, 
consumption of certain foods such as meat products, peroxide-rich fruits, and vegetables can 
influence the test result (Sinatra, St. John, & Young, 1999).  Plant peroxides that are 
hemoproteins and bloods from meat products react with the hydrogen peroxide developer and 
produce oxidation of guaiac that may lead to a false positive test result (Sinatra et al., 1999; 
Young et al., 2014).  Since heme from animal blood is similar to heme from human blood, 
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gFOBT cannot distinguish them apart (Young et al., 2014).  Antioxidants also disrupt the 
chemical reaction between heme and the hydrogen peroxide developer, and can lead to a false 
negative test result (Young, 2004).   
FIT also examines blood in feces by utilizing antibodies rising against the globin portion 
of human hemoglobin.  Globin is specific to species, thus the test result is less likely affected by 
the influence of hemoglobin from dietary resources and diet restriction prior to the FIT is 
unnecessary (Carroll et al., 2014).  Human hemoglobin in stool binds to antibodies when it is 
mixed with the reaction mixture and gathers the complexes form of globin (Carroll et al., 2014).  
As a result, the fecal sample becomes turbid that can be measured by a turbidimeter (Carroll et 
al., 2014).  A higher rate of the turbidity indicates higher human hemoglobin concentration in 
feces (Carroll et al., 2014).  Globin in feces suggests bleeding from lower gastrointestinal (GI) 
tract such as the colon or rectum because globin from the upper GI tract including mouth, 
pharynx, esophagus, stomach, and duodenum are rapidly degraded while passing through  the 
path of upper GI tract (Enterix Inc, 2013; Smith, Young, Cole, & Bampton, 2006).   
The earlier gFOBT demonstrated a low sensitivity for detecting CRC (Imperiale, 
Ransohoff, Itzkowitz, Turnbull, & Ross, 2004), and thus was problematic as a modality for CRC 
screening.  Rehydrating the stool samples has improved sensitivity, and newer gFOBT such as 
Hemoccult II Sensa were developed to improve sensitivity (Smith et al., 2006).  Commonly used 
gFOBT tests require three stool samples ideally taken at three different times (Washington State 
Department of Health, 2010).  GFOBT cards have three sections with two windows on each 
section.  Patients are instructed to smear stool from two different parts of the sample in each 
window for three separate stool samples.  After completion of all three sections, the gFOBT card 
needs to be sent to a laboratory or health care facility for analysis.  Although most FITs continue 
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to use a similar sampling technique with gFOBT, sampling methods have been evolving with 
FIT.  A brush-based sampling method is a new- comer that requires for a user to swish the brush 
at the surface of the toilet bowel water after the stool is immersed (Young, 2004).  
InSure®FIT™, one of the new-comers using the brush technique, has two flaps where the 
swished brush will be dabbed (Enterix Inc, 2013).  Two flaps require separate stool samples in 
order to improve detection of blood (Enterix Inc, 2013).  After completion, the test is sent to 
designated laboratory for analysis.   
Convenience and acceptability combined with ease and simplicity in stool sampling are 
characteristics for the ideal FOBT (Young, 2004).  Researchers conducted a randomized cohort 
trial among urban residents aged between 50 and 69 years in Adelaide, Australia comparing 
participation rates among three groups; the Hemoccult SENSA (gFOBT) requiring three stool 
samplings using a spatula and the restriction of certain foods and drugs; FlexSure OBT (FIT) 
requiring three stool samplings using a spatula and no food and drug restriction; and 
InSure®FIT™ (FIT) requiring two samplings using a brush (Cole, Young, Esterman, Cadd, & 
Morcom, 2003).  Cole et al. (2003) identified the highest participation in the group using 
InSure®FIT™ with 39.6% while the group using FlexSure had a participation rate of 30.5%.   
The group using the Hemoccult SENSA was the lowest at 23.4% in participation.  This study 
demonstrated that convenience and acceptability play a vital role for people in determining 
whether or not to participate in CRC screening.   
Large randomized controlled trials in Europe have also validated that FOBT can reduce 
CRC mortality (Bosetti et al., 2011; Hardcastle et al., 1996; Mandel et al., 2000).  In order to be 
successful, a screening test must have several characteristic, including eligible individual’s 
willingness to participate, convenience to the test, and the essential sensitivity/specificity of the 
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test (Young et al., 2014).  Sensitivity and specificity of FOBT also must be compatible compared 
with other modalities such as colonoscopy and sigmoidoscopy.   
Methods 
Electronic databases including the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), EBSCOhost, Pubmed, ScienceDirect, Cochrane Systematic Review, and 
Google Scholar were searched using the keywords colorectal cancer screening, screening 
modalities, fecal occult blood test, fecal immunochemical test, efficacy, fecal occult blood test 
randomized controlled trial, and fecal occult blood test systemic review.  Inclusion criteria 
consisted of articles published between 2008 and 2015 that focused on the efficacy of FOBTs 
(gFOBT and FIT) in people aged 50 years and older.  In order to assess the applicability of 
articles to the study, article titles and abstracts were initially reviewed.  If titles and abstracts 
were not sufficient in providing eligibility, the entire article was reviewed.   
Search Results 
Twelve studies met the inclusion criteria.  Three studies were randomized controlled 
trials (RCT) including Hol et al. (2009), Lindholm, Brevinge, and Haglind (2008), and Quintero 
et al. (2012).  Cochrane Systematic Review included one study by Hewitson, Glasziou, Watson, 
Towler, and Irwig (2008).  The remaining eight studies consisted of observational studies; 
Grazzini et al. (2009), Parra-Blanco et al. (2010), Kershenbaum, Flugelman, Lejbkowicz, Arad, 
and Rennert (2012), Ou et al. (2013), Shin et al. (2012), Parente et al. (2014), Quintero et al. 
(2014), and Turenhout et al. (2014).  The sample size for three RCT studies ranged from 15,011 
to 68,308.  The Cochrane Systematic Review examined nine articles describing four RCTs 
consisting of more than 320,000 participants in a period of 8 to 18 years.  Sample size for nine 
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observational studies ranged from 1,918 to 325, 881.  Shin et al. (2012) did not specify the 
number of participants but described the total number of tests performed.  
Researchers studied the effects of utilizing FOBTs as a CRC screening modality on the 
outcomes of performances in CRC detection rates and/or participation in CRC screening 
(Grazzini et al., 2009; Hol et al., 2009; Kershenbaum et al., 2012; Ou et al., 2013; Parra-Blanco 
et al., 2010; Quintero et al., 2012; Quintero et al., 2014; Shin et al., 2013; Turenhout et al., 2014) 
and reduction in CRC incidence and/or mortality (Hewitson et al., 2008; Lindholm et al., 2008; 
Parente et al., 2014).  Other outcomes included cost effectiveness (Parente et al., 2014) and 
occurrence of major complications (Quintero et al., 2012). 
Key Findings 
CRC & Advanced Neoplasia Detection 
Most studies focused on FOBTs efficacy in detecting CRC and advanced neoplasia, 
including an adenoma ≥ 10.0mm, villous adenoma, and early stage cancer based on the NCI 
definition (NCI, 2014b).  When discussing the efficacy of a screening test, sensitivity, specificity, 
positive predictive values (PPV), and negative predictive values (NPV) are commonly used 
values.  Sensitivity refers to the ability of a test to detect diseased individuals correctly, while 
specificity is defined as an ability of the test to identify disease-free individuals correctly (Parikh, 
Mathai, Parikh, Sekhar, & Thomas, 2008).  The probability of having a disease with a positive 
result is known as PPV, while NPV is probability of not having a disease with a negative test 
result (Parikh et al., 2008).   
The majority of studies reviewed agreed on the superior efficacy of FIT compared with 
the efficacy of gFOBT in detecting advanced neoplasia and CRC (Hewitson et al., 2008; 
Grazzini et al., 2009; Ou et al., 2013; Parra-Blanco et al., 2009; Shin et al., 2013).  Sensitivities 
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of FIT and gFOBT were 61% versus 23.8% respectively in detecting significant neoplasia with 
food intake restrictions including red meats, vegetables, and vitamin C for three days prior to 
stool sampling (Parra-Blanco et al., 2009).  Hewitson et al. (2008) found the sensitivity of 
gFOBT as ranging from 55% to 57% compared with the sensitivity of high-sensitive gFOBT 
ranging from 82% to 92%.  Screening with high sensitivity gFOBT annually also demonstrated 
achieving high rates of cancer detection (Kershenbaum et al., 2012; Parra-Blanco et al., 2010).  
For example, Kershenbaum et al. (2012) found that annual Hemoccult Sensa (gFOBT) was 
achieving high success in detecting CRC by about 84-93% of expected CRC occurrence in 
Jewish populations aged 50-64 years and 90-99% for Jewish populations aged 65-74 years.   
Interestingly, Shin et al. (2013) and Turenhout et al. (2014) recognized a difference in 
sensitivity of the FIT between in men and women.  For instance, males had higher sensitivity 
by13% to 23% than females at all cut-off values; 50ng/ml, 75ng/ml, 100ng/ml, and 200ng/ml 
(Turenhout et al., 2014).  Shin et al. (2013) reported smaller difference (5.87%) of sensitivity 
between men and women.  Two studies (Castiglione, et al., 2007; Malila, Oivanen, Malminiemi, 
& Hakama, 2008) in Europe also reported similar findings of higher sensitivity of FIT in men 
than in women.   
Parra-Blanco et al. (2009) found that PPV of FIT was 43.4% while PPV of gFOBT was 
39.0%.  Parra-Blanco et al., (2009) also learned that NPV of FIT was 97.5% and NPV of FOBT 
was 95.4%.  Hol et al. (2010) reported similar results with findings from Parra-Blanco et al., 
(2009).   
Reducing CRC Incidence and Mortality 
Large RCTs (Bosetti et al., 2011; Hardcastle et al., 1996; Mandel et al., 2000) in Europe 
have demonstrated the effectiveness of gFOBT in reducing CRC mortality.  Several studies 
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showed similar results (Hewitson et al., 2008; Lindholm et al., 2008; Parente et al., 2014).  
Hewitson et al. (2008) concluded that combining the annual and biennial screening with FOBT 
reduced CRC mortality by 16% from conducting Cochrane systemic review of four RCTs.  A 
study in Sweden for Goteborg citizens aged 60 to 64 years with high-sensitivity gFOBT 
following restrictions on foods (red meats, peroxidase-rich fruits and vegetables) and medicines 
(iron supplements and vitamin C) for two days prior to collecting stool samples, also showed a 
similar reduction rate of 16% in CRC mortality (Lindholm et al., 2008).  However, the incidence 
of CRC or overall mortality rate of CRC after 19 years from the start of the trial showed no 
difference between the screened and controlled groups (Lindholm et al., 2008).  Utilizing 
rehydrated gFOBT (high sensitivity FOBT) two to three times for CRC screening appears to 
facilitate reducing CRC mortality.  Parente et al. (2014) also demonstrated 5-years mortality 
considerably reduced (19%) in screening group (19%) with a single FIT compared with non-
screening group (37%) or pre-screening group (41%). 
Participation Rate 
Utilization of FOBT seems to facilitate improved CRC screening rates among eligible 
adults who are reluctant to undergo invasive screening tests (i.e. flexible sigmoidoscopy & 
colonoscopy).  FIT (61.5%) showed higher participation rates than gFOBT (49.5%) or flexible 
sigmoidoscopy (32.5%) (Hol et al., 2010).  Quintero et al., (2012) also found similar results with 
a participation rate 34.2% for FOBT and 24.6% for colonoscopy (Quintero et al., 2012).  Parente 
et al. (2014) found overall acceptance of FIT was 50%.  However, some have found that women 
have higher participation rates in screening with gFOBT or FIT compared with men (Hol et al., 
2010; Parra-Blanco et al., 2009). 
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Strategies and Cut-Off Values 
Two types of FOBT were evaluated in the studies reviewed; gFOBT and FIT.  FIT 
consisted of two types; qualitative testing for positive or negative for blood in feces (qlFIT) and 
quantitative measuring hemoglobin content in feces (qnFIT).  GFOBT was studied by Hol et al. 
(2009), Kershenbaum et al. (2012), Lindholm et al. (2008), Ou et al. (2013), and Parra-Blanco et 
al. (2010).  Quantitative FIT was studied by Grazzini et al. (2009), Hol et al. (2009), Parente et al. 
(2014), Parra-Blanco et al. (2010), Quintero et al. (2012), Quintero et al. (2014), and Turenhout 
et al. (2014). Both quantitative and qualitative FIT was studied by Ou et al. (2013) and Shin et al. 
(2013) while FIT and gFOBT were examined by Ou et al. (2013) and Parra-Blanco et al. (2010).   
Ou et al. (2013) argued that FIT performance was determined by the cut-off values of 
hemoglobin in feces ranging from 25 to150 ng/mL.  Three studies by Grazzini et al. (2009), Ou 
et al. (2013), and Turenhout et al. (2014) evaluated FOBT performances at different cut-off 
values of hemoglobin levels in feces.  One study found that males had a higher sensitivity for 
CRC than females at all cut-off values, including 50ng/ml, 75ng/ml, 100ng/ml, and 200ng/ml 
(Turenhout et al., 2014).  For example, the sensitivity of FIT for CRC at 75ng/ml was 
considerably higher (93%) in males compared with females (71%).  On the other hand, FIT 
sensitivity for advanced adenomas demonstrated no significant difference for males and females.   
A study identified that biennial one-time FIT with a cut-off value of 100ng/ml had a higher 
detection rate for CRC and advanced adenoma than gFOBT (Grazzini et al., 2009), while another 
study reported that  hemoglobin concentration in feces was increased in participants who had 
polyps bigger than 10mm or advanced adenomas (Ou et al., 2013).  Repeated FIT screening with 
a cut-off value at 50ng/ml annually for three consecutive years demonstrated its compatibility to 
colonoscopy in CRC screening (Quintero et al., 2014).  Repeated FIT has been found to 
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substantially decrease the need for follow-up screening with colonoscopy by 2-4 folds (Parra-
Blanco et al., 2009; Quintero et al., 2014).   
Utilizing different strategies of FOBTs seems to influence their performances.  Strategies 
can involve sampling frequency, cut-off values of hemoglobin level I feces, and restriction of 
diet and medicines.  Employing an annual high sensitivity gFOBT (Kershenbaum et al., 2012; 
Parra-Blanco et al., 2010), a single fecal sample with FIT (Hol et al., 2009; Shin et al., 2013) one 
time, every two years (Grazzini et al., 2009; Parente et al., 2014; Quintero et al., 2012), or every 
year for 3 consecutive years (Quintero et al., 2014) were examined in studies.  Some researchers 
asked participants receiving gFOBT to follow restriction of diet and medicines two to three days 
prior to stool sampling (Lindholm et al., 2008; Parra-Blanco et al., 2010; Kershenbaum et al., 
2012).  In addition, cut-off values of hemoglobin in feces were used at different levels; 50ng/ml 
(Ou et al., 2013; Parra-Blanco et al., 2010; Quintero et al., 2014; Turenhout et al., 2014; ), 75-
79ng/ml (Grazzini et al., 2009; Quintero et al., 2012; Turenhout et al., 2014), and 100ng/ml (Hol 
et al., 2010; Parente et al., 2014). 
Staging Distribution and Location 
Stage distribution of a cancer is considered a strong predictor for the 5-year survival rates 
commonly used in determining cancer outcomes (ACS, 2014b).  In other words, detecting CRC 
at early stages significantly increases 5-year survival rate.  Parente et al. (2014) found that 
overall 5-year survival rate was increased to 81.1 percent in screening group compared with non-
screening group (63%) or pre-screening groups (58.9%).  CRC detection at stage 1 was 54.7% in 
the screening group while only 10% for the non-screening group and 15.8% for the pre-screening 
group.  Stage distribution also markedly differed between the screening group and non-screening 
group (Parente et al., 2014).  Kershenbaum et al. (2012) also identified that 70% of the cancer 
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detected among the Jewish population was at stages Duke’s B and lower, meaning that the 
cancer invades only through the muscle layer (NCI, 2014c).      
FIT and gFOBT exhibited differences in detecting advanced neoplasia depending on 
location.  According to the study by Parra-Blanco et al. (2010), advanced neoplasia at proximal 
location was often found by FIT.  Comparing the stage distribution of left and right-sided colon 
cancer, right-sided colon cancers were detected lower and in relatively advanced stages 
(Kershenbaum et al., 2012).  Findings by Shin et al. (2013) also indicated that the FIT showed 
the highest sensitivity for the left and sigmoid colon at 87.9%, with the above finding by 
Kershenbaum et al. (2012).  In addition, Shin et al. (2013) found that the sensitivity of FIT was 
highest for distal colon cancer at 65.9% and rectal cancer at 58.4% compared with proximal 
colon cancer.  However, Quintero et al. (2012) reported that there was no significant difference 
between FIT and colonoscopy in detecting CRC based on location. 
Cost effectiveness 
CRC screening appears to be cost effective.  FOBT reduced CRC incidence by detecting 
polyps or CRC at early stage which cost considerably less in treatment compared with the cost of 
advanced CRC.  A study in the Lecco province of Italy by Parente et al. (2014) found the mean 
total cost for first year diagnosis were €16,435 ($18,571 based on the current money value), 
€20,862 ($23,574), €29,845($33,725), and €37,288($42,135) for stage I, II, III, and IV 
respectively. 
Complications  
One study by Quintero et al. (2012) described 0.5% of participants experienced some 
form of complication from undergoing a colonoscopy.  These complications included bleeding in 
12 participants, hypotension or bradycardia in 10 participants, desaturation in 1 participant, and 
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bowel perforation in 1 participant.  On the other hand, only 0.1% of participants in FIT group 
experienced bleeding, hypotension, or bradycardia.  However, the complications in FIT group 
were related to colonoscopy as a follow up test after the participants had a positive result with 
FIT. 
Discussion 
Critique of Studies 
Employing FIT compared with gFOBT was associated with a higher participation rate 
and superior efficacy in detecting advanced neoplasia and CRC, particularly in men.  FIT was 
compatible with a colonoscopy in CRC screening when a cut-off value of 50ng/ml annually was 
repeatedly used for three consecutive years.  FOBT has two types; gFOBT and FIT, which is also 
divided into qualitative test and quantitative test.  Quantitative tests reviewed were measured 
with several cut-off values of hemoglobin in feces which influenced the performance of FIT.  
FOBT was also cost effective with few complications.  Other interesting findings include the 
followings; higher FIT sensitivity for CRC in males than in females with all cut-off values, 
differences between gFOBT and FIT in detecting advanced neoplasia depending on the location 
of the CRC, and differences in finding CRC at stage distribution with FOBT between screening 
and non-screening groups. 
Limitations  
Eight of twelve studies were observational.  A limitation related to an observational study 
is its inability to show causal relationships between interventions and outcomes (Polit & Beck, 
2010).  Thus, the effect of employing FOBT for the reduction in CRC incidence and mortality 
rate cannot be fully established.  Another limitation of an observational study is related to its 
strength of evidence, which is inferior compared with RCTs.  This results in weakening the 
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strength of the findings from these studies.  Other limitations are related to inconsistency in 
utilization of FOBT.  For instance, reviewed studies used different cut-off values of hemoglobin 
in feces (25ng/ml, 50ng/ml, 75ng/ml, 100ng/ml, 125ng/ml, and 200ng/ml), different types (high 
sensitivity gFOBT, qualitative FIT, and quantitative FIT), and different frequency (annual versus 
biennial).  These differences limit reasonable comparison of outcomes.  
Implications for Practice   
Improving CRC screening rates among eligible adults is critical.  Findings from reviewed 
studies support the utilization of annual FIT for CRC screening as currently recommended by 
USPSTF.  Although the efficacy of FIT is not as high as the efficacy of colonoscopy, providers 
must understand that FIT has demonstrated significant improvement in its ability to detect 
advanced neoplasia and CRC recently.  As a result, they should offer FIT for those who are 
hesitant to undergo colonoscopy or unable to be screened with colonoscopy due to their low 
socioeconomic status. 
Conclusion 
A low sensitivity of gFOBT for detecting polyps and CRC is considered to be a major 
barrier in its utilization as a recommended screening modality by USPSTF.  FIT compared with 
gFOBT demonstrated superiority in detecting CRC and advanced neoplasia and participation to 
screening.  In consequence, FIT may be a reasonable test that can be accepted by a broad range 
of populations.  Further research needs to be conducted to determine the most effective cut-off 
value of hemoglobin that is most effective in detecting polys and CRC.  The USPSTF 
recommendations guidelines for CRC screening in 2008 will be up-dated in the near future.  The 
research findings provided vital evidences that should be considered in up-dating recommended 
screening modalities for CRC screening. 
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Abstract 
The purposes: To explore, provide a framework for implementing the Influenza Shot and Home 
Testing Kit for FOBT program (FluFOBT), and conduct a cost benefit analysis of the program. 
Methods: A cost benefit analysis of the FluFOBT program was conducted to estimate the cost 
of implementing this innovation based on the information provided in implementing the same 
program at the China town Public Health Center. 
Results: A cost-benefit analysis showed a cost-savings per person of $11,810 for men and 
$12,445 for women.  With those cost savings, the 1-4 FluFOBT programs can be implemented.  
Each program is capable of screening 75-100 eligible adults. 
Conclusion: The FluFOBT program appears to be effective not only in improving CRC 
screening rates but also in saving costs.  Implementing the FluFOBT program seems to be a 
promising way to reach both those of low socioeconomic status and racial/ethnic minorities.  The 
FluFOBT   program should be used as an optional program that serves for many eligible adults 
with inexpensive costs. 
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Introduction 
Colorectal Cancer (CRC) can be a prevented disease by utilizing routine screening 
recommended by U.S. Preventive Service Task Force (USPSTF, 2008).  In 2011, 51,783 people 
died from CRC (Centers for Disease Control and Prevention [CDC], 2014a).  For adults aged 50-
75 years with average- risk, the USPSTF CRC screening guidelines recommend using any of the 
following modalities; fecal occult blood test (FOBT) such as high-sensitivity FOBT or fecal 
immunochemical test (FIT) annually, sigmoidoscopy every 5 years with FOBT every 3 years, 
and colonoscopy every 10 years (USPSTF, 2008).  Although these tests are effective not only in 
reducing CRC incidence rate but also in decreasing CRC mortality rate, only 64.5% of eligible 
adults aged 50 between 75 old with average risk participated to CRC screening  in the United 
States in 2008 (CDC, 2013).  Factors that contribute to the low CRC screening rate may vary, but 
lack of access to health care services among low socioeconomic groups and minority groups may 
be one of major contributors.  The purposes of this paper are to explore, provide a framework for 
implementing, and conduct a cost benefit analysis of the Influenza Shot and Home Testing Kit 
for FOBT program (FluFOBT) that targets low-income populations aged 50 to 80 years.   
The Institute of Medicine (IOM, 2003) pointed out the existence of disparities in  
health care in a comprehensive review of racial and ethnic disparities in health care in 2003.  
Additionally, according to a report by the Kaiser Family Foundation Commission on Medicaid 
and the uninsured, racial/ethnic minorities are more likely to lack insurance coverage and to live 
in low income households compared with non-Latino Whites ( Garfield, Damico, Stephens, & 
Rouhani, 2014).  The report also indicated that uninsured adults are less likely to receive 
preventive care and services that focus on disease prevention and heath maintenance, including 
screening for cancer (Garfield et al., 2014).  Ward et al. (2004) also highlighted inequalities in 
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cancer incidence, mortality, and survival related to poverty.  The incidence rates and advanced 
stage of diagnosis of CRC are likely higher among minority populations (Grubbs et al., 2013).  
Wong, Gildengorin, Nguyen, and Mock (2007) found that the CRC screening rate was low 
among Asian-American groups in California compared with non-Latino Whites.  Morbidity and 
Mortality Weekly Report (U. S. Department of Health and Human Services, 2011) provided 
similar findings on CRC incidence and screening in United States in 2008 and 2010; 
considerably lower overall CRC screening rate among Asian/Pacific Islander (CDC, 2013).  
Regrettably, Berry et al. (2009) showed that African Americans are disproportionally burdened 
with CRC, having the highest CRC incidence rate across all races (CDC, 2013; Lawsin, 
DuHamel, Weiss, Rakowski, & Jandorf, 2006).   
CRC can be costly for both patients and the healthcare system (Howard, Tangka, Seeff, 
Richardson, & Ekwueme, 2009).  The cost for caring for cancer in 2010 was projected to be 
$124.57 billion nationally (Mariotto, Yabroff, Shao, Feuer, & Brown, 2011).  Of that, the cost of 
caring for patients with CRC was predicted to be $14.14 billion, the second highest cost in 2010 
after caring for breast cancer, and the highest cost of initial care (Mariotto et al., 2011).  In a 
study estimating the cost attributable to colon cancer by cancer stage, comorbidity, and patient 
characteristics, it was found that the mean total cost for colon cancer one year after diagnosis 
was $29,196 (Luo, Bradley, Dahman, & Gardiner, 2009).  Luo et al. (2009) also demonstrated 
that the cost for caring for a patient with CRC in situ, or local stage, was $27,551, while the cost 
for a patient with distant stage CRC was $29,933.   They found that patient comorbidities 
influenced costs.  For example, one, two, three, or more of comorbidities increased the cost by 
$2,762, $3,095, and $7, 717, respectively (Luo et al., 2009). 
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CRC screening has been shown to be cost-effective compared to no screening.  In a 
systematic review for USPSTF, Telford, Levy, Sambrook, Zou, and Enns (2010) showed that the 
cost savings for CRC screening when compared with no screening was less than $50,000 per 
life-year-gain (LYG).  A similar review of 32 published articles regarding to the cost-
effectiveness of CRC screening by Lansdorp-Vogelaar, Knudson, and Brenner (2011) found that 
cost-savings per LYG were more than $56,000 and $3,400 to $16,000 respectively by employing 
annual gFOBT and biennial gFOBT when compared with no screening in the U.S.  On the other 
hand, the cost-savings per LYG for colonoscopy was up to $34,000 (Lansdorp-Vogelaar et al., 
2009).  Additionally, lost productivity per CRC death was estimated at $288,468 in 2006 (CDC, 
2011).  Evidence clearly suggests that the healthcare system needs new innovations to improve 
CRC screening rates.  
Frazier, Colditz, Fuchs, and Kuntz (2000) demonstrated that CRC screening compared 
with no screening substantially decreases CRC mortality by 80 percent and prevents CRC 
incidence by 60 percent at costs similar to other cancer screening tests.  Telford et al. (2010) 
found that a reduction in CRC incidence and mortality by 44 percent and 81 respectively by 
performing FOBT annually.  Other researchers also showed similar results.  Hewitson, Glasziou, 
Watson, Towler, and Irwig (2008) conducted a Cochrane systemic review of four RCTs and 
concluded that annual and biennial screening with FOBT reduced CRC mortality by 16 percent.  
Lindholm, Brevinge, and Haglind (2008) found that employing FOBT reduced CRC mortality by 
16 percent.  Clearly, utilizing FOBT may be an effective way to increase CRC screening rates, 
and one innovation, the “FluFOBT program,” appears to be a promising strategy in promoting 
CRC screening.   
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The FluFOBT program offers an influenza shot and a home FOBT Kit if eligible patients 
are due for CRC screening when they come in for a primary care visit during the flu season.  
This innovative program could be implemented in public health centers and primary care clinic 
settings to increase CRC screening rates among low-income, uninsured or underinsured eligible 
adults.  The purposes of this paper are to explore, provide a framework for implementing, and 
conduct a cost benefit analysis of the influenza Shot and Home Testing Kit for FOBT program 
(FluFOBT) that targets low-income population age 50 to 75 years. 
Description of the Innovation 
It is critical to find a solution that will promote CRC screening for low-income, 
uninsured/underinsured population.  A hopeful solution for accomplishing this goal may be 
utilizing a program known as the FluFOBT.  The FluFOBT was developed by Dr. Michael Potter, 
a physician at University of California San Francisco Department of Family and Community 
Medicine, and his research team.  Development, implementation, and evaluation of the program 
were funded by CDC and American Cancer Society (ACS), the HMO Cancer Research Network, 
and the Alexander and Margaret Stewart Trust.  In 2013, the Prevent Cancer Foundation awarded 
the program a “Cancer Prevention Laurel for Innovative Programs,” given to the innovators and 
leaders who made a significant contribution to cancer prevention. 
The strength of evidence for this program was graded as moderate, meaning that “the 
available evidence is sufficient to determine the effects of the preventive service on health 
outcomes” based on the grading definition by USPSTF Grading Definition (2013). 
A pilot test of the program was launched during the flu season at the Chinatown Public 
Health Center (CPHC) in San Francisco in 2008.  Eight primary care clinicians at the CPHC in 
San Francisco provide care mostly monolingual Cantonese-speaking Chinese immigrants who 
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live in the Chinatown neighborhood.  The clinic handles roughly 14,000 visits each year.  The 
target population for this program was low-income patients aged 50 to 80 years who had not 
received a recommendation for CRC screening in the previous year.  A nurse fluent in Cantonese 
screened eligibility for CRC screening by reviewing electronic health records (EHR) prior to a 
patient seeing a healthcare provider.  The nurse asked patients if they were interested in getting a 
flu shot and administered the shot to those who desired it.  During this time, the nurse evaluated 
eligible patients by asking if they were interested in learning about CRC screening.  
The nurse provided a brief introduction to CRC screening and showed a 4-minute video in 
Cantonese that explained CRC screening in detail to those who were interested.  The nurse then 
offered answers to any questions the patients may have had and provided a home FOBT kit and a 
pre-paid envelope with written return address to those who desired to be screened.  The nurse 
entered the patients’ responses about receiving an influenza shot and the FOBT kit to the EHR.  
Patients who were given a home FOBT kit were provided with instructions in Cantonese on its 
use and given a pre-paid return envelope.  The patients returned the completed kit using the pre-
paid envelope to the program’s participating laboratory.  Patients received negative results by a 
mail, but those returning positive results were contacted to schedule a follow-up diagnostic 
evaluation. 
Cost Benefits Analysis 
Currently, no formal cost-benefit analyses of the program is available in the literature 
except for the studies performed by the researchers involved in Dr. Potter’s program.  The cost-
effective analysis on CRC screening using FOBT by Lejeune, DanCourt, Arveux, Bonithon-
Kopp, and Faivre (2010) demonstrated that the price of FOBT kits strongly influenced the cost-
effectiveness results.  A large study in the Netherlands by Rossume et al. (2010) reported that a 
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single FIT screening compared with no screening resulted 13,400 life-years gained and €320 
million (≈ $361.6 million) saved over a period of 10 years.  In addition, CRC screening saves 
$10,000 to $25,000 per year of life, according to Pignone, Saha, Hoerger, and Mandelblatt 
(2002).  A study in the Lecco province of Italy by Parente et al. (2014), showed mean total cost 
for the first year of diagnosis were €16,435 ($18,571 based on the current money value) vs. 
€20,862 ($23,574) vs. €29,845($33,725) vs. €37,288($42,135)  for stage I vs. II vs. III vs. IV, 
respectively. 
Cost 
The cost of this innovation will be estimated based on the information provided in the 
evaluation of the program at the CPHC in San Francisco by Dr. Potter and his colleagues.  The 
program does not require new staff members or additional building space because it utilizes the 
current nursing staff at the existing clinic settings.  However, the program does involve costs for 
training the nursing staff (a 1-hour session), purchasing program materials, and supplementary 
FOBT kits.  Educational materials, including a multilingual educational video for patients, can be 
downloaded from htt://flufit.org site at no cost.  Screening costs per person vary by test; however, 
the estimated cost for FOBT kits range from $5 (Lansdorp-Vogelaar et al., 2011), $10 (Singhal et 
al., 2014) to $30 (Taber, Aspinwall, Heichman, & Kinney, 2014). Singhal et al. (2014) used a 
median estimated standardized worldwide cost for FOBT and colonoscopy at $10 and $1,000 
respectively (rounded to closest whole numbers).  The price for FOBT in the U.S. is higher than 
those in Europe based on the findings by Lejeune et al. (2010).  The prices for FIT were ranged 
from $17.25 to $95 (Lansdorp-Vogelaar, et al., 2009; Mayo Clinic Medical Laboratories, 2013).      
In order to estimate the cost for training nursing staff, hourly wages of registered nurses 
(RN), licensed practical nurses (LPN), and nursing assistants were obtained from Bureau of 
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Labor Statistics at the U.S. Department of Labor (2014).  The average hourly wage for RNs, 
LPNs, and nursing assistants in Kentucky in 2013 were estimated as $27.65, $18.21, and $11.20 
respectively (U.S. Department of Labor, 2014).  According to Mayo Clinic Medical Laboratories 
(2013), the cost for running tests of guaiac based FOBT and FIT were $24 and $95 and were 
reimbursed by Medicare at the flat rate of $22.  With two licensed practical nurses (LPNs) and 
six nursing assistants (NAs), the cost for training nursing the staff would be $103.62 ($36.42 for 
two LPNs, and $67.20 for six nursing assistants).  The cost for program leaders responsible for 
organizing and implementing the program will be covered as part of their regular job salaries.  
As a result, there would be no extra cost spending. 
Six providers (4 physicians & 2 advanced practice registered nurse [APRN]) see an 
average of 500 patients per month.  Reflecting to current American population demographics, 
about 165 patients out of every 500 would be older than 50 years.  Of those, approximately 60 
patients, based on the current CRC screening rate of 64.5%, may be eligible for CRC screening.  
The months were counted based on 4 months of the flu months (October through January).  
Nearly 240 FOBT kits (60 patients for 4months) will be needed.  Demand for FOBT/FIT kit may 
vary.  Based on the demand for 240 FOBT/FIT kits, the costs for gFOBT will be $2,400 - 
$7,200/$4,140 - $22,800 (removing two extreme costs of $5 and $59). 
The cost for making postcards for advertising the program are $50 for 1 box (400 
postcards) at Vistaprint® (about 33% of 1,200 patients per month) and the postcards can be sent 
for $0.34 each ($136).  The posters can be downloaded and do not cost extra.  The cost for 
making postcards and sending them out is about $190.  The total cost for implementing 
FluFOBT program ranged from (to the nearest dollar) $1,873 to $3,873 vs. $9,348 to $17,123 
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based on using gFOBT vs. FIT (see Tables 1.2 & 1.2).  The large discrepancy between the low 
limit and the high limit resulted from the difference in the reported FOBT pricing.       
On the other hand, a colonoscopy costs are considerably high compared to the cost of 
gFOBT or FIT.  The costs for a colonoscopy vary and are largely determined by service fees.  
Services necessary for a colonoscopy without a biopsy include facility services, physician 
services, and anesthesia services (Healthcare BlueBook, 2015).  According to a report by the 
Healthcare BlueBook (2015), the fees for facility services, physician services, and anesthesia 
services were $692, $421, and $524, respectively, based on performance as outpatient procedure 
with average surgery time of 45 minutes.  Thus the total costs of necessary services for a 
colonoscopy sums up to about $1,637.  However, the actual costs charged for a colonoscopy 
differs immensely: $533 to $1,570 (Lansdorp-Vogelaar et al., 2009); $1,397 (DeBarros & Steele , 
2013); and $1,000 using the median estimated standardized worldwide cost reported by Singhal 
et al. (2014).  Thus, based on the estimated average cost for a colonoscopy reported by the 
sources above, it may be expected that costs range per person between $1,000- $1,650 (removing 
the extreme outlier $533 from this estimation).  A possible cause of the variance in the above-
quoted costs may be a result of the procedure being performed with or without anesthesia.         
Benefits  
Pignone et al. (2002) and Lansdorp-Vogelaar et al. (2009) demonstrated savings of 
$10,000 to $25,000 per year of life and nearly $26,000 per LYG in the program with annual 
FOBT screening.  On the other hand, a study by Parente et al. (2014) in Italy showed the cost for 
first year diagnosis ranged from €16,435 ($18,571) to €37,288 ($42,135).  The FluFOBT 
program can screen for 75 to 100 patients at a cost of $3,196.82- $7,996.82 or $21,996.82 to 
$40,636.82 (See Tables 1.1 & 1.2).  The average total annual costs for caring for patients with 
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CRC were estimated at between $12,231 to $18,359, based on the Surveillance Epidemiology 
and End Results (SEER) Medicare approach, considered to be the most accurate in identifying 
CRC patients (Yabroff et al., 2009).  However, the annual medical expenditure costs using 
Medical Expenditure Panel Survey (MEPS) were significantly less with $8,091 for males and 
$8,412 for females compared with those who were without cancer (CDC, 2014b).  In addition, 
the annual productivity losses were estimated at $3,719 for males and $4,033 for females due 
largely to employment disability of 75% (CDC, 2014b).  Patients with CRC also experience 
intangible losses that were not included in the cost-benefit analysis and that cannot be expressed 
in monetary values, including limited physical activities, interference with physical and mental 
tasks by cancer treatments (CDC, 2014b), and quality of life. 
Conclusion of Cost-Benefit Analysis 
The FluFOBT program has proven its effectiveness in increasing CRC screening rates.  
Evaluation of the piolet program launched in 2008 demonstrated a significant increase of CRC 
screening rates to 75.3% from 57.3% compared with an increase of 1.7% among eligible patients 
who did not participate in the program during the program’s first influenza season (Walsh, 
Gildengorin, Green, Jenkins, & Potter, 2012).  A cost-benefit analysis shows a cost-savings per 
person of $11,810 for men and $12,445 for women (see Table 2), which are similar to the cost 
savings of $10,000 to $25,000 per year of life demonstrated by Pignone et al. (2002).  The cost 
of implementing a FluFOBT program were estimated at between $3,196.82- $7,996.82 when 
using gFOBT and $21,996.82- $40, 636.82 when using FIT (Tables 1.1& 1.2).  Nearly 1-4 
programs can be implemented with a cost savings of $11,810 -$12,445.  One FluFOBT program 
can be implemented with a cost saving from 2-3 persons by using FIT.  When a FluFOBT 
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program is capable of providing 75-100 adults with CRC screening at a cost-savings per person 
of $11,810 -$12,445, the cost benefits are significant. 
Implementation of the Innovation 
The FluFOBT program may be implemented in primary care clinics by utilizing “the 
Three Steps of Change” by Kurt Lewin who is recognized as “the founder of the modern social 
psychology” (Greathouse, 1997).  The change model can be implemented in three steps, detailed 
below: the unfreeze step, the move (transition) step, and the refreeze step.  The first step in 
implementing a new program is to gain supports from top-level administrators and directors by 
providing contextual information of the innovation, its goal, and a comprehensive plan.  Once 
approval for implementing the innovation is obtained, the change model can be applied to 
implement the project.  The unfreeze step involves building with in a whole group a mood 
necessity for change.  Understanding group dynamics in regards to driving and restraining forces 
may provide valuable information in terms of recognizing individual goals, needs, and fears (Šuc, 
Prokosch, & Ganslandt, 2009).  Identifying the principle promoters and opponents of the project 
can be accomplished during workshops and by performing informal interviews.  Designating a 
program leader who can make plans for the program is essential.  During this phase, feedback, 
ideas, and suggestions should be collected and evaluated to minimize conflicts during program 
implementation. 
The move (transition) step involves processing all changes required to be made.  The first 
step should involve promoting the program’s launch with patients by creating posters and 
sending out postcards.  In regards to the FluFOBT program, standard steps include: identifying 
eligible patients aged 50 to 75 years for CRC screening who visit the clinic during flu season; 
asking if they are interested in getting a flu shot and providing a flu shot if interested; asking if 
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they are interested  in learning more about the FOBT; providing a brief introduction to CRC and 
FOBT; ask if they are interested in taking a home FOBT kit; providing a home kit along with a 
pre-paid return envelope and one-page instruction sheet and answering, if asked, any questions 
about the test; and documenting the procedure in the patients’ charts.  Individuals need to learn 
new behaviors related to the implementation of the project through training, education, and 
communication.  In order to ensure the program runs efficiently, nursing staffs need to attend a 
1-hour group session, which includes the standard procedures of the program, 1-2 weeks prior to 
program launch.  To try and assess the program’s impact on day-to-day operations, a small scale 
test should be conducted 1-2 days per week before the program is fully operational.  The 
program’s participating laboratory also needs to ensure it can manage the increased volume of 
the FOBT test.  Additionally, in order to maintain the effectiveness of the program it is crucial 
that gastrointestinal specialists be available to perform colonoscopies in an appropriate time 
frame for those who have positive results with the FOBT test.  This can be the most stressful 
period for individuals who have to learn or adjust to the changes. 
The last step involves building reinforcements for sustaining the program after it has been 
implemented, in particular, monitoring the ongoing process and outcomes.  For example, 
program leaders might conduct feedback meetings after auditing patients’ charts.  This ongoing 
process may lead to recognition that refinements or adjustments to the project have become 
necessary, particularly if compliance with the change is less than expected.  Program leaders and 
top management must provide supports to frontline members who are responsible for running the 
program during this time in order to prevent them from relapsing back to old patterns of practice.   
Also, if the participation rate is lower than established goals within a specified time frame, it is 
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necessary to take extra measures to encourage the remaining patients to return completed tests by 
contacting them directly through e-mail, text message, or telephone call.    
The effect of the program on its recipients can be determined by performing an 
evaluation (Issel, 2009).  However, it can become a distraction from the essence of the program 
if too many outcomes are considered in an evaluation by producing higher evaluation costs and 
producing a vast volume of data to analyze (Issel, 2009).  Focusing on the key outcome will 
reduce such distractions (Issel, 2009).   The program outcome should monitor the completion 
rate of CRC screening among FluFOBT program participants versus those who did not 
participate in the program while visiting the clinic during flu season. 
Conclusion 
Because of the significant gaps in CRC screening rates among Americans (CDC, 2013; 
Wong et al., 2007), it is important to make efforts not only to improve CRC screening rates 
among eligible adults of a low socioeconomic status and racial/ethnic minorities, but also to be 
cost effective in achieving that goal.  Despite the effectiveness of screening tests in reducing the 
incidence and mortality of CRC, the current CRC screening rate is unsatisfactory.  Implementing 
the FluFOBT program appears to be effective not only in improving CRC screening rates but 
also in cost saving.  Implementing the FluFOBT program appears to be a promising way to reach 
both those of low socioeconomic status and racial/ethnic minorities.  The FluFOBT program 
should be encouraged to be used as an optional program that is effective for many eligible adults 
with inexpensive costs. 
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              Table 1.1  The Cost for Implementing FluFOBT Program 
 COST NUMBER TOTAL 
gFOBT kit $10 - $30 240 $2,400-$7,200 
Cost for testing $24 - $22 
(reimburse by 
Medicare) 
=$2 
240 $480 
Nursing assistant $11.20 6 $67.20 
LPN $18.21 2 $36.42 
Stamps for return 
Kit 
$0.34 240 $81.60 
Postcards $50 1box $50 
Stamps for 
postcards 
$0.34 240 $81.60 
Total   $3,196.82- $7,996.82 
               
 
              Table 1.2  The Cost for Implementing FluFOBT Program 
 COST NUMBER TOTAL 
FIT kit $17. 25- $95 240 $4,140- $22,800 
Cost for testing $95-$22 (reimburse 
by Medicare)=$73 
240 $17,520 
Nursing assistant $11.20 6 $67.20 
LPN $18.21 2 $36.42 
Stamps for return 
Kit 
$0.34 240 $81.60 
Postcards $50 1box $50 
Stamps for 
postcards 
$0.34 240 $81.60 
Total   $21,976.82-$40.636.82 
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   Table 2  Cost per Colorectal Cancer  
 Male Female 
Annual Medical 
expenditure 
$8,091 $8,412 
Annual Productivity 
Loss 
$3,719 $4,033 
Total $11,810 $12,445 
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Abstract 
Purpose: The purpose of this project was to examine the relationship between advanced practice 
registered nurse (APRN) knowledge about the U.S. Preventive Service Task Force (USPSTF) 
colorectal cancer (CRC) screening recommendations guideline and self-reported referral rates for 
CRC screening among APRNs. 
Methods: A descriptive internet survey was conducted to examine APRN knowledge about the  
USPSTF CRC screening recommendation guidelines and their self-reported referral rates for 
CRC screening by administering the Modified Test Your Knowledge Survey to APRNs.   
Results: APRNs self-reported CRC screening referral rates were not associated with their 
knowledge levels.  In addition, APRNs lacked knowledge not only in categorizing risk level of 
individuals, but also in utilizing the FOBT appropriately.   
Conclusions: Although there was no relationship between APRNs knowledge level of USPSTF 
CRC screening recommendations guidelines and their self-reported CRC screening referral rates, 
adequate knowledge of the current guidelines are essential for APRNs in order to provide 
evidence-based safe care.  Thus, efforts must be made to improve APRNs risk assessment skills 
and proper utilizations of FOBT. 
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Introduction 
Colorectal cancer (CRC) is the third most common cancer in the U.S., with a lifetime risk 
of 5.7 % for men and 5.1 % for women in the U.S. (U.S. Preventive Service Task Force 
[USPSTF], 2008).  Despite the fact individuals can choose among a number of preferred CRC 
screening tests recommended by the latest USPSTF, unless significant improvement is made in 
screening rates, CRC prevalence may continue to grow among the aging American population 
(USPSTF, 2008).  Roughly 93% of diagnoses were made among adults older than 50 years of 
age (Weinberg, 2008).  Although CRC incidence rates have been declining annually by 3.4% and 
mortality rates by 3.0%  in recent years (Centers for Disease Control and Prevention [CDC], 
2013a), participation in CRC screening reached only 64.5% of eligible adults in 2008 (CDC, 
2013a).  The Healthy People 2020 cancer objective aims to increase the CRC screening rate to 
70.5% (U.S. Department of Health and Human Services [HHS], 2015). 
CRC is one of the most highly preventable cancers if individuals participate in screening.  
The risk for incidence and death of CRC caused by late detection and late intervention can be 
significantly reduced by adhering to the most recent USPSTF (2008) recommendation guidelines 
for CRC screening, published in 2008.  The USPSTF recommendations are (a) to routinely 
screen adults aged 50 to 75; (b) to not routinely screen adults aged 76 to 85; and (c) to not screen 
adults older than 85 (USPSTF, 2008).  Understanding barriers to CRC screening is critical in 
encouraging eligible adults to participate in screening.         
Barriers to CRC screening result from multiple factors.  Jones, Devers, Kuzel, and Woolf 
(2010) identified bowel preparation and fear as the most widespread barrier to screening in their 
study.  Green et al., (2008) also described the fear of pain related to the colonoscopy procedure 
and a diagnosis of CRC as perceived barriers by patients.  Jones et al., (2010) also identified 
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barriers including financial and language difficulties.  Lack of a provider’s recommendation for 
CRC screening also was a common theme in discussing barriers to CRC screening.  Lasser, 
Ayanian, Fletcher, and Good (2008) identified “no doctor’s recommendation” as one of barriers 
in their study, and Kelly et al., (2007) and Jones et al., (2010) found that lack of physician 
recommendation was a barrier to CRC screening.  Not surprisingly, other researchers identified a 
provider recommendation as the most powerful influence on patient decision to undergo CRC 
screening (Davis et al., 2013; Haverkamp, Perdue, Espey, & Cobb, 2011; Klaunde, Vernon, 
Nadel, Breen, Seeff, & Brown, 2005; Sarfaty, 2008).    
Primary care providers (PCPs) usually initiate CRC screening by making a referral for 
one of the recommended screening tests (Katz et al., 2012; Ornstein, Nemeth, Jenkins, & Nietert, 
2010).  Thus, insufficient knowledge of CRC and USPSTF CRC screening guidelines may result 
in eligible adults being overlooked for CRC screening (USPSTF, 2008).  In a survey of internal 
medicine resident knowledge (n=81), Barrison, Smith, Oviedo, Heeren, and Schroy (2003) 
concluded that the residents lacked necessary risk assessment skills and knowledge about CRC 
screening recommendations.  Gennarelli et al. (2005) arrived at similar results regarding low 
physician knowledge of CRC screening guidelines for average-risk patients.  Additionally, 
O’Farrell, Green, Reid, Bowen, and Baldwin (2012) found that CRC screening rates were higher 
among patients who received a physician’s recommendation compared with those patients who 
did not.  Based on these findings, insufficient knowledge regarding screening guidelines among 
PCPs may negatively affect their ability to offer appropriate screening recommendations to 
eligible adults.        
Advanced practice registered nurses (APRNs) make up nearly 25% of primary care 
providers in the U. S. (Institution of Medicine [IOM], 2011).  Growth in the number of APRNs is 
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gradually rising while medical students and residents entering primary care are declining (IOM, 
2011).  Understanding APRNs knowledge of CRC screening recommendation guidelines is 
essential.  It is also important to recognize the relationship between their knowledge level and 
their referral rates in order to improve CRC screening rates.  Nevertheless, there are no published 
studies on APRN knowledge about the USPSTF CRC screening recommendation guidelines.  In 
an effort to determine how CRC screening rates could be increased, two questions arose.  What 
do APRNs know about the USPSTF CRC recommendation guidelines?  Is there a relationship 
between APRN knowledge regarding the USPSTF CRC recommendations and their self-reported 
referral rate for CRC screening?  
Purpose 
The purpose of this project was to examine the relationship between APRN knowledge 
about the USPSTF CRC screening recommendation guidelines and self-reported referral rates for 
CRC screening among APRNs. 
The aims of this project were to determine; (1) demographic characteristics of APRNs; 
(2) APRNs knowledge levels about the USPSTF CRC screening recommendation guidelines; (3) 
the referral rate of APRNs by collecting participant self-reported screening rates; (4) whether 
educational background is associated with the self-reported referral rates; and (5) the relationship 
between an APRNs knowledge level about the USPSTF CRC screening recommendation 
guidelines and the self-reported referral rates for CRC screening.  
Methods 
Study Design and Sample 
A descriptive internet survey was conducted to examine APRN knowledge about the 
2008 USPSTF CRC screening recommendations and self-reported referral rates for CRC 
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screening.  The Test Your Knowledge Survey (Sarfaty, 2008, Appendix A) was modified and 
administered to APRNs through the Kentucky Coalition of Nurse Practitioners and Nurse 
Midwives listserv (KCNPNM) from January 5 through March 5, 2015. 
 Currently, 5,321APRNs are registered in Kentucky, with each role broken down as 
follows; nurse anesthetist (1,215), nurse specialist (178), nurse midwives (100), and nurse 
practitioner (3,828) (Kentucky Board of Nursing, 2014).  Inclusion criteria for this study were (a) 
APRNs over 18 years old who are subscribers to the KCNPNM listserv; (b) are currently 
practicing in Kentucky 12 hours or more each week in general practice, family practice, internal 
medicine, gastroenterology practice, and obstetrics/ gynecology.  Exclusion criteria for this study 
were APRN nursing students who were subscribers to the KCNPNM listserv. 
Subject Recruitment  
The initial contact with potential eligible participants was made by sending an e-mail via 
the KCNPNM listserv to all 1,526 subscribing member of KCNPNM on January 5
th
, 2015 after 
obtaining permission from the University of Kentucky Medical Institutional Review Board and 
the Executive Director of KCNPNM (Appendix B).  The e-mail included an invitation to 
participate in the study, information about the study, and a link to access the survey.  Follow up 
e-mails were sent as a reminder to complete the survey to all 1,526 subscribing members of 
KCNPNM four more times during January and February after the initial e-mail.  
Informed Consent Process  
The e-mail explained the purpose of this project, anticipated benefits and risks, limitation 
of confidentiality due to the nature of an online survey, contact information, and statements 
describing type of participation, and no penalties or loss of benefits for not participating or 
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withdrawing from the study if they should desire.  Participation was voluntary.  Completion of 
the survey constituted consent.   
Research Procedures 
The Test Your Knowledge Survey was developed as a part of a toolbox to guide primary 
care providers in promotion of CRC screening (Sarfaty, 2008).  The Test Your Knowledge 
survey was modified to include items related to demographics and referral rates.  The survey 
consists of twenty questions.  The first ten questions are related to improving screening rates in 
practice, and the remaining ten questions focused on the current screening recommendation 
guidelines.  The modified survey is organized into the following four sections; (a) practice and 
other demographic characteristics; (b) attitude toward improving CRC screening rates in 
practice; (c) knowledge of CRC screening modalities and recommendation guidelines; and (d) 
self-reported CRC screening recommendation rate.   
Items inquiring about APRN attitudes toward improving CRC screening rates focused on 
evidence-based essential elements that are effective in improving CRC screening rates (Sarfaty, 
2008).  These elements include provider recommendation, an office policy about assessing 
individual risk and insurance coverage, identifying local medical resources and considering 
patient preference, an office reminder system, and an effective communication system between a 
provider and patients. 
Items assessing APRN knowledge about CRC recommendation guidelines focused on 
categorizing the risk level of individual patients and applying appropriate CRC screening tests.  
The item evaluating APRNs’ self-reported referral rate was measured by using a four-point 
Likert scale that contains “very often”(90-100%), “often” (75-90%), “average”(50-75%), “not 
often”(less than 50%) after reviewing the USPSTF CRC screening recommendation guidelines 
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(Appendix C).  Each question was coded 1 for correct response and 0 for incorrect response and 
a total survey score was calculated for each participant.  Question 21 was added to evaluate self-
reported APRN referral rates.  Questions 22 -31 were added to examine the participant 
demographics.  Thus, the participants were asked about their age, gender, level of nursing 
education, years of practice as an APRN, the type of APRN license held, type of the clinical 
setting and county in which they practiced, working hours each week, and average number of 
patients they see each week.  REDCap was used to collect and store data.  REDCap is a secure 
web-based application that supports and manages data capture for small/medium-sized research 
studies (Harris et al., 2009).  Data were securely kept on Biomedical Informatics servers ran by 
the Institute for Pharmaceutical Outcomes and Policy (IPOP) physically located in the new 
Biological and Pharmaceutical Complex building at the University of Kentucky.   
Data Analysis 
Statistical analysis was performed using SPSS.  Descriptive statistics were utilized to 
describe the sample.  Frequencies were calculated for each variable.  A McNemar Chi-square test 
(2x2) was used to examine the relationship between APRN knowledge and self-reported referral 
rates for CRC.  If McNemar Chi-square statistic value is > 3.84 and p value is < 0.05, the null 
hypothesis will be rejected.  A p value <0.05 is considered statistically significant. 
Results 
Demographic characteristics 
Ninety-seven participants were recruited from January 5 to March 5, 2015.  Of those, 34 
participants were excluded based on the incompletion of survey, inability to provide self-
reported referral rates for CRC screening due to their practice backgrounds (a thoracic unit, an 
acute care unit, a retail clinic, & cardiology), practice out of Kentucky, working less than 12 
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hours per week, retired, or student.  Of the remaining 63 participants, a majority (n=59; 93.7%) 
were female, which reflects the national average (≈92%) of female nurses in nursing fields (U.S. 
Census Bureau, 2013).  Master’s prepared APRNs (nearly 75%) dominated the sample while 
20.7% were doctorally prepared APRNs.  APRNs had been in practice for an average of 11.6 
years and an average of 49.8 years old.  APRNs from 30 counties participated with the highest 
participation rate coming from Jefferson County.  Demographic characteristics are provided in 
Table 3. 
Regarding attitudes toward improving CRC screening rates in practice, only 44.4% (n=28) 
of APRNs recognized “a recommendation” as the most effective tool for encouraging patients to 
be screened.  One hundred percent (n=63) of APRNs acknowledged that “postcard reminders”, 
“reminder letters”, “prescription reminders”, and “telephone calls” would be effective in 
improving CRC screening rate, but only 53% of these responded that all four have been 
demonstrated to be effective.  Only 57.1% (n=36) responded to the effectiveness of all four of 
the chart prompts including “problem lists”, “screening schedules”, “electronic medical record 
reminders”, and “chart stickers”.  On the other hand, nearly 96.8% (n=61) of APRNs identified 
“provider feedback” as an effective way to improve CRC screening.  Over 90% (n=57) of 
APRNs also acknowledged involving office staffs in the screening process can facilitate 
improving CRC screening.  Table 4 illustrates the results on APRNs attitude toward improving 
CRC screening rates in practice. 
Overall test scores for knowledge level of USPSTF CRC screening recommendation 
guidelines were 77.9%.  The first six questions which were focused on assessing attitudes toward 
improving CRC screening rates in practice were not included in the overall test scores because 
they were not related in the evaluation of  APRNs knowledge of CRC screening recommendation 
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guidelines by USPSTF (see Figure 1).  Answers were coded either 1 point for a correct response 
or 0 point for incorrect response.  The maximum score was 14 points.  A total survey score was 
calculated for each participant.  The distribution of scores is exhibited in Figure 1.  Three APRNs 
answered all questions correctly, while one APRN scored 6, the lowest score.  The mean score ± 
standard deviation was 10.9 ± 2.06 and median of 11.  
The majority of APRNs (n=40, 63.5%) answered “false” (correct answer) when asked if 
the digital rectal examination is an acceptable CRC screening practice.  Regarding whether a 
clinician should perform a stool blood test in the office to make sure that at least one CRC 
screening test was completed, 60.3% (n=38) of APRNs answered “true” (incorrect answer).  
Only 52.4% (n=33) of APRNs answered “false” (correct answer) when asked if a stool blood test 
should be repeated when it is returned with only one positive window.  71.4% (n=45) of APRNs 
answered “true” (incorrect answer) when asked if a positive stool blood test without following 
the diet restrictions should be repeated.  APRNs knowledge level regarding rectal examination 
and stool blood test are displayed in Table 5.1. 
Participants also showed a lack of knowledge when asked to categorize the risk level of 
patients as average, increased, or high based on the current screening guidelines.  For example, 
74.6% (n=47) of APRNs answered “high” (incorrect answer) when asked them to categorize the 
risk level of a 20 year-old woman whose mother died of colorectal at age 47.  More than half of 
the APRNs (n=32) also provided incorrect answers to the question that asked to categorize the 
risk level of a 30 year old male whose older brother was diagnosed with an adenomatous polyp 
at age 59.  The average APRNs correct response on categorizing the risk level for four individual 
patients was only 40.5%.  Table 5.2 illustrates the results on APRNs knowledge of categorizing 
the risk levels of individual patients. 
57 
 
APRNs demonstrated their knowledge regarding CRC screening ages for “average-risk” 
patients.  Nearly 90% of participants knew individuals with average risk for CRC should screen 
at age 50.  The majority of participants also knew colonoscopy has the highest sensitivity and 
specificity among the recommended modalities and should be used as a follow-up screening test.  
Table 5.3 shows the APRNs performance on choosing appropriate modalities for individual 
patients. 
When APRNs were asked to rate their referral for CRC screening using a four-point 
Likert scale that contains “very often”(90-100%), “often” (75-90%), “average”(50-75%), “not 
often”(less than 50%), 51% (n=32) of them reported that they made referrals for CRC screening 
“very often”, while 33.3% (n=21) reported making referrals “often”.  Only 15.9% (n=10) of 
APRNs reported that they made referral for CRC screening “average” or “not often”.  
Participants who answered “N/A” were excluded from this study.  Those responses were 
compared with test scores (n=24 who scored ≥ 11 and n=39 who score <11) to determine if there 
was a relationship.  McNemar’s Chi-square test value was 𝛘2 = 6.21 and p-value = 0.01.  Given 
the assumption that APRNs who scored higher on the test will have higher referral rates (null 
hypothesis), the McNemar statistic value 𝛘2 = 6.21 and p-value = 0.01 rejected this assumption.  
As a result, APRNs knowledge level of CRC screening recommendations guideline and their 
referral rates were not related.  APRNs test scores and their self-reported referral rates for CRC 
screening is displayed in Table 6. 
There was no difference in test scores and very little difference in self-reported referral 
rates by education levels.  The majority of APRNs (83%) with MSN degrees reported their 
referral rates as “very often” or “often”, 84.6% of APRNs with doctoral degrees reported their 
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referral rates as “very often” or “often” while only 63.8% of APRNs with MSN and 62.5% of 
APRNs with DNP and PhD scored ≥ 11. 
Discussion 
Provider’s recommendation for CRC screening has been identified as the most effective 
in convincing patients to undergo screening procedures (Davis et al., 2013; Haverkamp et al., 
2011; Klaunde et al., 2005; Sarfaty, 2008).  All APRNs in this present study agreed with the 
effectiveness of reminder methods such as postcards, letters, and phone calls in increasing CRC 
screening rates although not all of them agreed on those reminders as being equally effective.  
 Other researchers have recognized “no recommendation” as one of the barriers to CRC 
screening (Jones et al., 2010; Kelly et al., 2007; Lesser et al., 2008).  Less than 50% of APRNs in 
this study agreed with the above findings.  Green et al. (2013) conducted a study on examining 
an automated intervention to increase uptake of CRC screening, including EHR-linked mailings, 
telephone assistance, automated assistance plus nurse navigation.  Green et al. (2013) found 
groups with those interventions, compared with groups with no intervention, were more likely to 
be current for CRC screening. 
Findings from the present study on APRNs were consistent with studies on physicians 
(Barrison et al., 2003; Gennarelli et al., 2005; Nadel et al., 2010).  The average APRNs correct 
response on categorizing the risk level for four individual patients was only 40.5%.  Perhaps 
those findings may be explained by inadequate explanation of how to categorize the risk level, 
and the complexity of the risk assessment for developing CRC provided by USPSTF CRC 
screening recommendation guidelines. 
Providers’ knowledge of CRC screening recommendation guidelines is a critical 
component in improving CRC screening among eligible adults.  A previous study on internal 
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medicine residents by Barrison et al. (2003) demonstrated that risk assessment skills on an 
individual for developing CRC and knowledge about CRC screening recommendations are 
insufficient.  Gennarelli et al. (2005) also found physicians lacked knowledge of CRC screening 
guidelines for average-risk patients. 
Although utilization of FOBT has been decreasing in recent years, FOBT is one of the 
recommended modalities for CRC screening by USPSTF.  Over 60% of participants considered 
the one-time FOBT administration in the office as being an acceptable practice.  Additionally, 
over 70% of APRNs lacked an understanding that colonoscopy was recommended when a FOBT 
showed a positive result regardless of the diet restrictions not being followed.  One potential 
cause for APRNs poor knowledge level regarding FOBT may be a declining utilization of FOBT 
at only 10.4% in recent years (CDC, 2013b). 
 Many studies have validated that FOBT can reduce CRC incidence and mortality (Bosetti 
et al., 2011; Hardcastle et al., 1996; Hewitson et al., 2008; Lindholm et al., 2008; Mandel et al., 
2000; Parente et al., 2014).  For example, conducting Cochrane Systemic Review of four RCTs 
showed that FOBT reduced CRC mortality by 16% (Hewitson et al., 2008).  APRNs 
demonstrated insufficient knowledge of utilization of the FOBT.  A single digital rectal 
examination with FOBT cannot be recommended as the only test due to its poor sensitivity 
(4.9%) for detecting CRC (Collins, Lieberman, Durbin, Weiss, & the Veteran Affairs 
Cooperative Study # 380 group, 2005).  Nadel et al. (2010) described the one-time FOBT given 
by PCPs in the office may be worse than no screening because it fails not only in detecting 95% 
of cases of advanced neoplasia but also provides a false sense of reassurance.   
On the other hand, APRNs were knowledgeable about application of other modalities.  
Almost all APRNS knew colonoscopy should be used as the follow-up test.  Interestingly, the 
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present study found that APRNs knowledge level was not correlated to their self-reported CRC 
screening referral rates.  Of those (n=24) who scored less than 11, 87.5% indicated that they 
made referrals very often or often.  In addition, analysis found that no statistically significant 
association in self-reported referral rates between APRNs with MSN and APRNS with DNP or 
PhD. 
Limitations 
This study has several limitations.  First, an unvalidated instrument was used to measure 
APRNs knowledge level.  However, validity and reliability for this instrument have not been 
tested.  Second, the small sample size is a limitation.  Sixty-three participants in the present study 
represent only 1.2% of total APRNs in Kentucky.  Thus, the findings from this study cannot be 
generalized to the whole APRN population.  Lastly, a self-reported referral rate for CRC 
screening method was utilized.  This method may potentially lead to bias since true referral rates 
could not be determined.  A patient’s chart audit by using EHR may help to minimize the bias. 
Implications for Practice and Research 
Findings from this study indicated APRNs knowledge of utilization of FOBT (one of the 
recommended CRC screening tests) and risk assessment skills were lacking.  Suggestions to 
improve APRNs knowledge in these areas include providing education programs related to 
utilization of FOBT and risk assessment skills by employing pre-test and post-test.  Offering 
continuous educational unit (CEU) credit hours for the educational program may encourage 
APRNs to participate in these programs.  It may be necessary to produce a simple algorithm of 
assessing the risk level for developing CRC of individuals for APRNs to use it as a quick 
reference.  In addition, it is essential to create a better instrument to measure APRNs level of 
CRC screening recommendation guidelines. 
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Conclusions 
The present study aimed to determine if there was a relationship between APRNs 
knowledge level of CRC screening recommendation guidelines and APRNs self-reported CRC 
screening referral rates.  Findings from this study indicated that APRNs lacked knowledge not 
only in categorizing the risk level of individuals, but also in utilizing FOBT appropriately.  Thus, 
needs for improvement in APRNs knowledge related to risk assessment skills and utilization of 
FOBT were identified.  APRNs should keep in mind that FOBTs, especially the high-sensitivity 
FOBT and FIT, have made significant improvements in their sensitivity.  Because of improved 
sensitivity of FOBT or FIT, these tests can be a reasonable alternative that can reach to a broad- 
range of eligible adults.  Although APRNs self-reported CRC screening referral rates were not 
associated with their knowledge level, sufficient knowledge of the current guidelines are 
essential for APRNs in order to provide evidence-based safe care.  Efforts must be made to 
improve APRNs risk assessment skills and proper utilizations of the FOBT. 
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Tables and Figure 
 
              Table 3  Demographic Characteristics of APRN 
 Frequency Percent 
Gender Male                                                                                     
Female  
Non-specified                                                                               
3
59 
1 
4.8% 
93.7% 
1.5% 
Education MSN                                                                                   
DNP                                                                                   
PhD  
Others/missing 
47
10 
3 
3 
74.6% 
15.9% 
4.8% 
4.8% 
Years in Practice 1-5 years  
6-10 years 
11-15 years 
16-20 years 
21-25 years 
30 and over years 
22 
12 
6 
12 
0 
5 
34.9% 
19% 
9.5% 
19% 
0% 
7.9% 
APRN Designation Nurse Practitioners 
Nurse Midwives 
Clinical Nurse Specialist 
Nurse Anesthetist 
54 
5 
3 
0 
85.7% 
7.9% 
4.8% 
0% 
Population Focused Family Practice 
Adult (Adult-Gero) 
Women’s Health 
Acute Care 
Psychiatric Care 
36 
13 
11 
2 
1 
57.1% 
20.6% 
17.5% 
3.2% 
1.6% 
County Jefferson 
Fayette 
Hardin 
Breckinridge 
Caldwell 
Daviess 
Franklin  
Pulaski 
22 more counties with an APRN 
14 
9 
3 
2 
2 
2 
2 
2 
1 
22.2% 
14.3% 
4.8% 
3.2% 
3.2% 
3.2% 
3.2% 
3.2% 
35.2% 
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                  Table 4  APRNs Attitudes toward Improving Screening Rates in Practice  
  Frequency Percent 
Q 1. The most effective 
tool at an APRN’s 
disposal fir encouraging 
patients to be screened 
is 
A recommendation 
(correct answer) 
An educational pamphlet 
An educational video 
None of the above 
All of the above 
28 
 
7 
1 
26 
1 
44.4% 
 
11.1% 
1.6% 
41.3% 
1.6% 
Q 2. Which of the 
following have been 
demonstrated to be 
effective in raising 
cancer screening rates 
Postcard reminders 
Reminder letters 
Prescription reminders 
Telephone calls 
All of the above (correct 
answer) 
6 
9 
3 
9 
36 
9.5% 
14.3% 
4.6% 
14.3% 
57.1% 
 
Q 3. Effective chart 
prompts include 
Problem lists 
Screening schedules 
Electronic medical record 
reminders 
Chart stickers 
All of the above (correct 
answer) 
0 
12 
14 
 
1 
36 
 
0% 
19% 
22.2% 
 
1.6% 
57.1% 
Q 4. A theory-based 
communication 
strategy is more 
effective than generic 
education 
True (correct answer) 
False 
48 
13 
76.2% 
27.1% 
Q 5. Provider feedback 
is an effective way to 
improve office 
screening rates 
True (correct answer) 
False 
61 
2 
96.8% 
3.2% 
Q 6. Reassignment of 
office staff to involve 
them in the screening 
process can facilitate 
improved screening 
rates 
True (correct answer) 
False 
57 
4 
90.5% 
6.4% 
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             Table 5.1  APRN Knowledge Level about the USPSTF CRC Screening Recommendation Guidelines 
 Frequency Percent 
Q 7. The digital rectal 
exam in an accepted 
colorectal cancer screening 
practice. 
True 
False (correct answer) 
23 
40 
36.5% 
63.5% 
Q 8. Clinician should do a 
stool blood test in the 
office to make sure that at 
least one CRC screening 
test is completed. 
True 
False (correct answer) 
38 
25 
60.3% 
39.7% 
Q 9.  If a stool blood test 
kit is returned and only 
one window is positive, the 
test should be repeated. 
True 
False (correct answer) 
30 
33 
47.6%                      
52.4% 
Q 10. A positive stool 
blood test should be 
repeated if the diet 
restriction were not 
followed, 
True 
False (correct answer) 
45 
18 
71.4% 
28.6% 
 
             Table 5.2  APRN Knowledge Level about the USPSTF CRC Screening Recommendation Guidelines 
 Frequency Percent 
Q 11. A 45 year old woman 
whose father was 
diagnosed with colorectal 
cancer at age 70? 
Average (correct answer) 
Increased  
High 
 
24 
33 
5 
38.1% 
52.4% 
7.9% 
 
Missing =1 
Q 12. A 30 year old male 
whose older brother was 
diagnosed with an 
adenomatous polyp at age 
59. 
Average 
Increased (correct answer) 
High 
14 
30 
18 
22.2% 
47.6% 
28.6% 
Missing =1 
Q 13. A 50 year old female 
whose uncle was 
diagnosed with 
adenomatous polyps at 
age 55. 
Average (correct answer) 
Increased 
High 
33 
24 
6 
52.4% 
38.1% 
9.5% 
 
Q 14. A 20 year old woman 
whose mother died of 
colorectal at age 47 
Average 
Increased (correct answer) 
High 
0 
15 
47 
0% 
23.8% 
74.6% 
Missing =1 
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             Table 5.3  APRN Knowledge Level about the USPSTF CRC Screening Recommendation Guidelines 
  Frequency Percent 
Q 15. At what age should 
“average-risk” patient 
begin colorectal cancer 
screening? 
Puberty                                          
Age 25                                         
Age 40 
Age 50 (correct answer) 
Age 60 
0 
2 
5 
56 
0 
0% 
3.2% 
7.9% 
88.9% 
0% 
Missing=0 
Q 16. At what age should a 
patient with family history 
of colorectal cancer or 
adenomatous polyps 
affecting one first-degree 
relative diagnosed at age 
55 begin screening? 
Puberty                                          
Age 25                                         
Age 40 (correct answer) 
Age 50 
Age 60 
1 
8 
46 
8 
0 
1.6% 
12.7% 
73.0% 
12.7% 
0% 
Missing=0 
Q 17. What screening 
modality offers the 
greatest sensitivity and 
specificity and should be 
recommended to those at 
increased risk? 
Stool blood test 
Stool blood 
test/Flexible Sig. 
Flexible sigmoidoscopy 
Colonoscopy (correct 
answer) 
Double–contrast barium 
enema 
 
1 
5 
4 
53 
0 
 
0 
 
1.6% 
7.9% 
6.3% 
84.1% 
0% 
 
0% 
Missing=0 
Q 18. What screening 
modality might be best to 
recommend to a patient 
who is distrustful of 
physicians or very 
uncomfortable with 
invasive procedures? 
Stool blood test 
(correct ans.) 
Stool blood 
test/Flexible Sig. 
Flexible sigmoidoscopy 
Colonoscopy 
Double–contrast barium 
enema 
51 
5 
0 
3 
4 
 
0 
81% 
7.9% 
0% 
4.8% 
6.3% 
 
0% 
Missing=0 
Q 20. Which of the 
following screening test(s) 
are recommended by one 
or more authoritative 
groups for patient at risk 
of hereditary non-
polyposis colon cancer or 
familial adenomatous 
polyposis? 
Stool blood test 
Flexible Sigmoidoscopy 
Stool DNA testing 
Colonoscopy (correct 
answer) 
Double–contrast barium 
enema 
All of the above 
1 
3 
4 
52 
1 
0 
0 
 
1.6% 
4.8% 
6.3% 
82.5% 
1.6% 
0% 
0% 
Missing=2 
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             Table 6 Test Scores and Self-Reported Referral Rates for CRC Screening 
 Referral Rate 
≥ 75% 
Referral  Rate 
< 75% 
Total 
Test Score ≥ 11 32 (82.1%) 7 (17.9%) 39 
Test Score <11 21 (87.5%) 3 (12.5%) 24 
Total 53 10 63 
 
 
 
           Figure 1  Distribution of Test Scores 
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Colorectal cancer (CRC) is the second leading cause of cancer deaths in both men and 
women in the United States.  The Centers for Disease Control reports that 51,783 people died 
from CRC in 2011.  CRC can be prevented by participating in recommended screening tests 
including fecal occult blood test (FOBT) such as high-sensitivity FOBT or fecal 
immunochemical test (FIT) annually.  However, only 64.5% of eligible adults were screened for 
CRC in 2008.  Factors contributing to the low CRC screening may vary, but several barriers 
including invasive screening methods (fear, bowel preparation, and unwillingness to undergo), 
lack of access to health care services, and lack of provider’s recommendation due to insufficient 
knowledge related to the current CRC screening recommendation guidelines have been identified.  
It is critical to overcome these barriers for improving CRC screening rates among eligible adults 
in the United States. 
Efforts must be made to improve CRC screening rates among eligible adults.  Several 
strategies for overcoming these barriers were identified from conducting the DNP practice 
inquiry project.  To increase utilization of high-sensitivity FOBT or FIT annually for those who 
are reluctant to undergo the invasive screening tests or for low-income adults who have lack of 
access to health care services may help to overcome barriers related to the invasive screening 
tests.  Although the sensitivity of FOBT is not as high as of colonoscopy, employing FOBT has 
demonstrated its effectiveness not only in reducing CRC mortality and incidence rates but also in 
increasing participation rates to CRC screening.  The current low utilization of FOBT at 10.4% 
in recent years should be increasing. 
Even though the present study found that there was no relationship between APRNs 
knowledge level about the USPSTF CRC screening recommendation guidelines and their self- 
reported CRC screening rates, providers’ sufficient knowledge of the current guideline is critical 
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in providing evidence-based safe care.  To provide educational programs to APRNs about the 
current CRC screening recommendation guidelines would improve their knowledge.  Developing 
a simple algorithm of assessing risk level of individual patients by USPSTF may be necessary 
for providers to use as a quick guide in determining risk level for an individual.  As a result, this 
may lead to more referrals for CRC screening.  On the other hands, a better instrument that can 
measure APRNs knowledge level appropriately should be developed in future research.   
Implementing the FluFOBT program may be a strategy in improving CRC screening 
rates.  Evaluation of the pilot program at the Chinatown Public Health Center (CPHC) in San 
Francisco launched in 2008 demonstrated a significant increase of CRC screening rates to 75.3% 
from 57.3% among those who were participated in the program.  Overcoming the above barriers 
appears to support efforts for increasing CRC screening rates.                 
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Appendix A 
Improving Screening Rates in Practice 
  
1.  The most effective tool at an APRN’s disposal for encouraging patients to be screened is:  
            a. A recommendation    
            b. An education pamphlet    
      c. An educational video     
            d. None of the above  
            e. All of the above  
 
2.  Which of the following have been demonstrated to be effective in raising cancer screening 
rates? 
            a. Postcard reminders   
            b. Reminder letters    
            c. Prescription reminders    
            d. Telephone calls  
            e. All of the above   
 
3.  Effective chart prompts include: 
            a. Problem lists  
            b. Screening schedules  
            c. Electronic medical record reminders  
            d. Chart stickers  
            e. All of the above 
 
Choose whether the statements are true or false. (True/ False) 
 
4.   A theory-based communication strategy is more effective than generic education. (T/ F) 
5.   Provider feedback is an effective way to improve office screening rates. (T/ F) 
6.   Reassignment of office staff to involve them in the screening process can facilitate improved 
screening rates. (T/ F) 
7.  The digital rectal exam is an accepted colorectal cancer screening practice.  (T / F)                 
8.  Clinicians should do a stool blood test in the office to make sure that at least one CRC 
screening test is completed.  (T / F)  
9.  If a stool blood test kit is returned and only one window is positive, the test should be 
repeated.   (T / F) 
10.  A positive stool blood test should be repeated if the diet restrictions were not followed.  
         (T /F) 
 
The Current Screening Guidelines Categorize the risk level of the following patients as 
average, increased, or high. 
 
 11. A 45-year-old woman whose father was diagnosed with a colorectal cancer at age 70      
                  Average                           Increased                            High 
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 12. A 30-year-old male whose older brother was diagnosed with an adenomatous polyp at age          
       59. 
                  Average                          Increased                             High 
13.  A 50-year-old female whose uncle was diagnosed with an adenomatous polyp at age 55.                  
                  Average                          Increased                               High 
14.  A 20-year-old woman whose mother died of colorectal at age 47.  
                 Average                          Increased                               High 
15.  At what age should “average-risk” patients begin colorectal cancer screening?  
        ____   Puberty    ____   Age 25   ____   Age 40    ____   Age 50   ____   Age 60   
                                                                                        
16.  At what age should a patient with a family history of colorectal cancer or adenomatous 
polyps affecting one first-degree relative diagnosed at age 55 begin screening?  
       ____   Puberty                 Age 25                 Age 40             Age 50   ____   Age 60 
17.  What screening modality offers the greatest sensitivity and specificity and should be    
recommended to those at increased risk? 
       ___      Stool blood test             ___   Stool blood test/Flexible sigmoidoscopy 
                   Flexible sigmoidoscopy            ____   Colonoscopy    
                   Double-contrast barium enema 
 18. What screening modality might be best to recommend to a patient who is distrustful of 
physicians or very uncomfortable with invasive procedures? 
      ____   Stool blood test               ____   Stool blood test/Flexible sigmoidoscopy   
      ____   Flexible   sigmoidoscopy        ____    Colonoscopy             
                  Double-contrast barium enema  
19.  Which of the following screening test(s) are recommended for a 40-year-old patient    whose   
65-year-old father had colorectal cancer or an adenomatous polyp?     
      ______   Stool blood test             ______   Flexible Sigmoidoscopy    
      ______    Stool DNA testing (sDNA)               ______ Colonoscopy  
      ______    Double-contrast barium enema (DCBE)  
      ______    All of the above 
 
 20.  Which of the following screening test(s) are recommended by one or more authoritative 
groups for patients at risk of hereditary non-polyposis colon cancer (HNPCC) or familial 
adenomatous polyposis (FAP)? (Choose one.)     
      ______    Stool blood test                                ______   Flexible Sigmoidoscopy   
      ______   CT colonography   (CTC)                 ______   Colonoscopy     
      ______    Double-contrast barium enema (DCBE) 
21.  How often do you make colorectal cancer screening referral for eligible patients in best your 
knowledge? 
               Very often (4)         Often (3)         Average (2)        Not often (1)       N/A (please 
explain why)                    
 
The following questions are for demographic purposes: 
 
22.   What is your age?                           
23.  What is your gender? 
                  Female                           Male                                Others 
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23.  What is the highest level of nursing education you have completed? 
                 MSN                      DNP                          PhD                     Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
24.  How many years have you practiced as an APRN? 
                     
25.  What is your APRN designation? 
                 Nurse Practitioner                   Nurse Anesthetist                     Nurse Midwife 
                 Clinical Nurse   Specialist        
26.  What is your population focus? 
                  Family                          Adult (or Adult-Gero)                 Acute Care    
                  Pediatrics                      Neonatology                                Women’s Health 
                    Psychiatric Mental Health 
27.  Please provide the type of clinical setting in which you practice. 
                    General Practice                   Family Practice                  Internal Medicine 
                    Obstetrics/ Gynecology                    Gastroenterology Practice 
                    Other (Please provide the type of your clinical setting) 
28.  Please indicate the State in which your practice. 
                      Kentucky                                     Other 
29.  If in Kentucky, which county do you practice in? 
30.  How many hours each week do you see patients? 
31.  About how many patients do you see each week? 
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Appendix B 
Letter of Approval from Kentucky Coalition of Nurse Practitioner and Nurse Midwives 
 
 
 
 
 
 
To whom it may concern:  
The Kentucky Coalition of Nurse Practitioners and Nurse Midwives is in support of Yong Seon 
Girdler, RN, BSN using our listserv to post a link to her survey regarding A Descriptive Study to 
Examine the Relationship between APRN Knowledge and Self-Reported Referral Rates for 
Colorectal Cancer Screening. As a member she has access to over 2000 members via our listserv 
and internal blogs and messaging systems. We fully support her project.  
 
Sincerely,  
  
Leila Faucette 
Executive Director 
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Appendix C 
SCREENING FOR COLORECTAL CANCER 
CLINICAL SUMMARY OF U.S. PREVENTIVE TASK FORCE RECOMMENDATION (2008) 
 
 
 
 
 
 
 
 
Screen with high sensitivity 
fecal occult blood testing 
(FOBT), sigmoidoscopy, or 
colonoscopy. 
 
 
Grade: A 
 
Do not screen routinely. 
 
 
 
 
 
Grade: C 
Do not screen. 
 
 
 
 
 
Grade: D 
For all populations, evidence is insufficient to assess the benefits and harms of screening with 
computerized tomography colonography (CTC) and fecal DNA testing. 
 
Grade: I (insufficient evidence) 
 
 
High sensitivity FOBT, sigmoidoscopy with FOBT, and colonoscopy are effective in 
decreasing colorectal cancer mortality. 
The risks and benefits of these screening methods vary. 
Colonoscopy and flexible sigmoidoscopy (to a lesser degree) entail possible serious 
complications 
Intervals for recommended screening strategies. 
Annual screening with high-sensitivity fecal occult blood testing. 
Sigmoidoscopy every 5 years, with high-sensitivity fecal occult blood testing every 3 
years. 
Screening colonoscopy every 10 years. 
The benefits of screening outweigh the 
potential harms for 50 to 75 year olds. 
The likelihood that detection and early 
intervention will yield a mortality benefit 
declines after age 75 because of the long 
average time between adenoma 
development and cancer diagnosis. 
Focus on strategies that maximize the number of individuals who get screened. 
Practice shared decision-making; discussions with patients should incorporate 
information on test quality and availability. 
Individuals with a personal history of cancer or adenomatous polyps are followed by a 
surveillance regimen, and screening guidelines are not applicable. 
 
The USPSTF recommends against the use of aspirin or nonsteroidal anti-inflammatory 
drugs for the primary prevention of colorectal cancer. This recommendation is available 
at www.preventiveservices.ahrq.gov 
 
 
 
For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and 
supporting documents please go to http://www.preventiveservices.ahrq.gov. 
 
*These recommendations do not apply to individuals with specific inherited syndromes (Lynch Syndrome or Familial Adenomatous 
Polyposis) or those with inflammatory bowel disease. 
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